Tonight, we bring important HIV treatment news that could change daily life for long-term survivors who have been managing complex medication routines for decades.
A new once-a-day HIV pill from Gilead Sciences aims to simplify treatment for people who cannot use the standard single tablet options. Dr. Chloe Orkin of Queen Mary University of London describes the reality for many of her patients when she says, “They keep asking: Why cannot I have a single pill? Or can I have injections? And you have to keep saying: No.”
She explains that many long-term survivors diagnosed in the 1980s and 1990s ended up with treatment options that did not work because, as she puts it, “Science has moved on for everyone else except for them. They are like a forgotten population.” However, things might change now. A new study published in The Lancet tested this once-a-day pill in a group of five hundred fifty people who are currently on complex multi-pill regimens. According to Dr. Orkin, the drug worked as well as the complex regimen.
The pill, made by Gilead Sciences, combines two of their HIV drugs — Bictegravir and Lenacapavir — into one tablet that’s smaller than a multivitamin. Another study, presented at the Conference on Retroviruses and Opportunistic Infections held in Denver, found this new pill is also as good as the single-tablet pill, Biktarvy, that is recommended as a first‑line option in U.S. treatment guidelines. This pill could become available in many countries by the end of the year, offering long-awaited simplicity and relief for long-term survivors who have carried the weight of complex treatment for far too long.
